SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

SC 13G - aTYR PHARMA INC (0001339970) (Subject)

SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). "We are excited to welcome Eric Benevich to the Board of Directors," said Timothy P. Coughlin, Chairman of the Board of aTyr. "His extensive background bringing new products to market and the knowledge and experti

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Jayant Aphale, Ph.D., as Vice President, Technical Operations. Dr. Aphale will serve as a member of the Company's executive leadership team, overseeing manufacturing activities at contract development and manufacturing organizations and implementing strategies related to the continuous improvement of commercial manufacturing, supply chain management, process development of new products and product lif

Leerink Partners initiated coverage of aTyr Pharma with a rating of Outperform and set a new price target of $16.00

Cantor Fitzgerald initiated coverage of aTyr Pharma with a rating of Overweight

Wells Fargo initiated coverage of aTyr Pharma with a rating of Overweight and set a new price target of $17.00

Jefferies initiated coverage of aTyr Pharma with a rating of Buy and set a new price target of $9.00

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025 Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on real-world evidence SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present three posters for its lead therapeutic candidate, efzofitimod, at the

SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA. Details of the presentation appear below: Conference: 43rd Annual J.P. Morgan Healthcare ConferenceDate: Thursday, January 16, 2025 Time: 8:15am PSTLocation: San Francisco, CAFormat: Corporate Presentation In addition to

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). "We are excited to welcome Eric Benevich to the Board of Directors," said Timothy P. Coughlin, Chairman of the Board of aTyr. "His extensive background bringing new products to market and the knowledge and experti

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the outcome of a third, pre-planned interim safety analysis conducted by an independent data and safety monitoring board (DSMB) for the ongoing Phase 3 EFZO-FIT™ study of the Company's lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis. The DSMB recommended that the study continue without any modifications. "We are pleased to report yet another positive safety review for efzofitimod, whic

SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, in Whistler, British Columbia, Canada. ATYR0101 is a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS) that binds to latent transformin

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, in Whistler, British Columbia, Canada. Details of the presentations appear below. The posters will be available on the aTyr website once presented. Title: A Newly Evolved Domai

Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025. Publication in European Respiratory Journal demonstrated statistically significant difference in time-to-first relapse for corticosteroid use and improvement in corticosteroid relapse rate for efzofitimod. SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2024 results and provided a corporate update.  "We achieved

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at several upcoming investor conferences scheduled to take place in November and December 2024. Details of the conferences appear below: Conference: Stifel Healthcare ConferenceDate: Monday, November 18, 2024 Time: 3:35pm ESTLocation: New York, NYFormat: Corporate Presentation Conference: Jefferies London Healthcare Conference Date: Wednesday, November 20, 2024Time: 3:00pm GMTLocation: London, UKFormat: Cor

Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups. 54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compared to 7.7% in the therapeutic group. SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a post hoc analysis of th

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024. Details of the conferences appear below: Conference: Wells Fargo Healthcare ConferenceDate: Thursday, September 5, 2024 Location: Everett, MAFormat: 1x1 Investor Meetings Conference: H.C. Wainwright 26th Annual Global Investment Conference Date: Wednesday, September 11, 2024Time: 10:30am EDTLocation: New York, NYFormat: Corpor